Sanofi — Director's Dealing 2020

Jul 29, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Inozyme Pharma, Inc. (INZY)
CIK: 0001693011
Period of Report: 2020-07-28

Reporting Person: Sanofi (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-07-28	Common Stock (par value $0.0001)	C	438875	$0.00	Acquired	438875	Indirect
2020-07-28	Common Stock (par value $0.0001)	P	81250	$16.00	Acquired	520125	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-28	Series A Convertible Preferred Stock (par value, $0.0001)	$0.00	C	3279720	Disposed		Common Stock (438875)	Indirect

Footnotes

F1: On July 28, 2020, Series A Convertible Preferred Stock (par value, $0.0001) converted into the Issuer's Common Stock on a 7.473-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of INZY and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of INZY.

F2: The reporting person acquired additional shares in the Issuer's initial public offering.